Eisai Presents New LEQEMBI Investigational Subcutaneous Formulation Interim Study Results And Clinical Improvement Data In Earlier Stages Of Early Alzheimer's Disease From Additional Analyses Of Clarity AD At CTAD
Portfolio Pulse from Benzinga Newsdesk
Eisai has presented new interim study results for its investigational subcutaneous formulation LEQEMBI, which is being studied for use in early Alzheimer's disease. The formulation has shown to clear 14% more plaque than IV, with pharmacokinetics 11% higher and similar ARIA rates to IV. Additionally, 76% of patients showed no decline and 60% showed clinical improvement at 18 months in a low-Tau subpopulation in an additional analysis of Clarity AD.
October 25, 2023 | 9:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eisai's new interim study results for LEQEMBI show promising results for early Alzheimer's disease treatment, which could potentially boost the company's stock in the short term.
The positive interim results for Eisai's LEQEMBI could potentially lead to increased investor confidence in the company, leading to a short-term boost in the company's stock. However, the final impact will depend on the final results of the study and regulatory approval.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Although Biogen is not directly mentioned in the article, it is known to be a competitor in the Alzheimer's disease treatment market. The positive results from Eisai's study could potentially impact Biogen's stock negatively in the short term.
The positive results from Eisai's LEQEMBI study could potentially lead to increased competition in the Alzheimer's disease treatment market, which could negatively impact Biogen's stock in the short term. However, the final impact will depend on the final results of Eisai's study and regulatory approval.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50